LightWave Acquisition Corp. Class A Ordinary Shares

Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved. eFFECTOR Therapeutics is focused on selective translation regulation inhibitors to treat cancer. The SPAC merger valued the company at $419 million, including a $60 million PIPE with an investment...

Clinical-stage biopharmaceutical company eFFECTOR Therapeutics is set to go public via the special purpose acquisition company Locust Walk Acquisition Corp (NASDAQ: LWAC) with an enterprise value of $419 million. Steve Worland, the president and CEO of eFFECTOR, and Chris Ehrlich, CEO of Locust Walk Acquisition Corp., appeared on Benzinga's ...